Blog
RSS FeedPosted by Michael Wonder on 24 Jun 2022
Health Canada expands approval of Enhertu for adults with HER2 positive metastatic breast cancer
23 June 2022 - Approval based on the ground-breaking DESTINY-Breast03 Phase 3 trial, showing Enhertu reduced the risk of disease ...
Posted by Michael Wonder on 23 Jun 2022
Maviret (glecaprevir/pibrentasvir) approved by Health Canada for paediatric patients with chronic hepatitis C
22 June 2022 - This approval is supported by 98.4 per cent cure rate across this group of patients who ...
Posted by Michael Wonder on 19 Jun 2022
Canadian regulator OKs Hugel's botulinum toxin product
16 June 2022 - Hugel said Thursday that it has obtained product approval from Health Canada for its botulinum toxin ...
Posted by Michael Wonder on 19 Jun 2022
Canadian drug prices: new regulations could save billions of dollars
15 June 2022 - New drug price regulations set to come into effect next month could lower spending on patented ...
Posted by Michael Wonder on 16 Jun 2022
Core network partners announced for CADTH’s post-market drug evaluation network
10 June 2022 - CADTH is pleased to announce the four successful core network partners of its inaugural post-market drug ...
Posted by Michael Wonder on 13 Jun 2022
Amylyx Pharmaceuticals announces Health Canada approval of Albrioza for the treatment of ALS
13 June 2022 - Health Canada decision signifies the first global regulatory approval for Amylyx and the first new therapy for ...
Posted by Michael Wonder on 08 Jun 2022
Health Canada approves Tabrecta: targeted cancer therapy for locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations
8 June 2022 - Newest treatment for lung cancer reinforces Novartis commitment to developing innovative therapies that improve outcomes for ...
Posted by Michael Wonder on 08 Jun 2022
The UK MHRA, Australian TGA and Health Canada approve Kimmtrak (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
8 June 2022 - Kimmtrak demonstrated statistically and clinically meaningful overall survival benefit, hazard ratio of 0.51, with median overall survival ...
Posted by Michael Wonder on 08 Jun 2022
Forus Therapeutics announces Xpovio (selinexor) is authorised for sale by Health Canada
7 June 2022 - FORUS Therapeutics is pleased to announce that on 31 May 2022, Xpovio (selinexor) was authorised for ...
Posted by Michael Wonder on 06 Jun 2022
BioCryst announces Health Canada has authorised Orladeyo (berotralstat), the only oral treatment for the prevention of hereditary angioedema attacks
6 June 2022 - BioCryst Pharmaceuticals today announced that Health Canada has approved oral, once daily Orladeyo (berotralstat) for the ...
Posted by Michael Wonder on 02 Jun 2022
Health Canada OKs Pfizer COVID-19 booster shot for teens ages 16 and 17
1 June 2022 - Canada on Wednesday authorised a single booster shot of Pfizer and partner BioNTech’s COVID-19 vaccine for ...
Posted by Michael Wonder on 01 Jun 2022
Health Canada authorises Vabysmo (faricimab injection) for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular oedema
1 June 2022 - Vabysmo (faricimab injection) is the first bispecific antibody that acts by neutralising both VEGF-A and Ang-2 ...
Posted by Michael Wonder on 25 May 2022
Bausch + Lomb receives Health Canada approval of Lumify redness reliever eye drops
24 May 2022 - Lumify is Canada's first and only over the counter eye drop with low dose brimonidine for ...
Posted by Michael Wonder on 24 May 2022
HLS Therapeutics obtains public reimbursement for Vascepa in Quebec
24 May 2022 - Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with ...
Posted by Michael Wonder on 23 May 2022
Draft CADTH recommendation for Spinraza (nusinersen sodium) fails adults in need of treatment for spinal muscular atrophy
20 May 2022 - CADTH does not accept new evidence demonstrating Spinraza's effectiveness and safety for treating spinal muscular atrophy – ...